Table 7 Clinical and demographic characteristics of the cohort of ALS individuals and healthy controls (HC) selected for the re-test experiment of neurofilament light (NfL), heavy (NfH) polypeptides and of apolipoprotein E (ApoE) using immunodetection.

From: Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis

 

PRL

Gender

Ethnic group

Age of onset (year range)

Diagnostic latency (month range)

ALSRS-R (/48) at sampling (score range)

PRL (range)

<0.4 slow

>0.7fast

female

male

caucasian

asian

B-ALS (n = 38)

 

12

26

17

21

37

1

39–76

1.3–71.3

13–44

0.3–1.8

L-ALS (n = 44)

 

27

17

19

25

44

—

33–81

2–129.9

23–47

0.1–2.4

       

Age at sampling

 

HC (n = 29)

        
 

NA

 

19

10

29

—

50–73

NA

  1. In the plasma/brain proteomic experiment, ALS patients were sub-grouped according to rate of disease progression, where fast progressing individuals had a progression rate to last visit (PRL) >0.7 and slow progressing individuals had a PRL < 0.4. To study the selected biomarkers expression in fast progressing disease (as in the plasma/brain proteomic experiment), only bulbar and limb-onset ALS individuals (B-ALS and L-ALS) with a PRL > 0.7 were selected for immunodetection analysis.
Back to article page